Methadone

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

Retrieved on: 
Tuesday, September 26, 2023
Public Health Agency of Canada, COVID-19, Cohort (statistics), Calendar, Opioid use disorder, OUD, Doctor of Philosophy, UDS, Incidence, Addiction medicine, RAAM, Journal, MCFP, Patient, Risk, Injection, Methadone, AM, Journal of Addiction Medicine, Public Health Agency, Fentanyl, Pharmaceutical industry, Indivior

This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.

Key Points: 
  • This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.
  • The percentage of individuals with urinary drug screen (UDS)-detected fentanyl use within the first month of treatment was 23% with SUBLOCADE; 22% with sublingual buprenorphine/naloxone, and 66% with methadone.
  • During the six months following the initiation of treatment, UDS-detected fentanyl use decreased to 13% with SUBLOCADE, 10% with sublingual buprenorphine/naloxone, and 51% with methadone.
  • "This study shows the potential positive impact of using SUBLOCADE in OUD treatment to help reduce non-fatal opioid overdoses in Canada, including from fentanyl use," said Christian Heidbreder, PhD, Chief Scientific Officer, Indivior.

Pinnacle Treatment Centers Expands Addiction Treatment Services with the Opening of Canton, Georgia Location

Retrieved on: 
Thursday, August 31, 2023
Employment, Naltrexone, Senior counsel, PTC, Peach, National Association Medical Staff Services, Opioid, Patient, Pinnacle, Methadone, Opioid use disorder, Counselor, Environment, Family therapy, Family, Substance abuse, Hospital

Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023

Key Points: 
  • Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023
    Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Canton, Georgia.
  • With a commitment to delivering personalized and evidence-based care, Pinnacle Treatment Centers aims to make a positive impact on individuals struggling with addiction in the local community.
  • Pinnacle provides underserved communities with affordable, accessible substance abuse treatment and the option of outpatient care.
  • “HealthQwest Canton offers treatment for anyone looking to escape the cycle of Opioid addiction,” says Nicole Habbe, Regional Director for Pinnacle Treatment Centers.

Pinnacle Treatment Centers to host Grand Opening celebration for Winchester Treatment Services

Retrieved on: 
Monday, August 28, 2023
Other Health, Hospitals, Health, Pharmaceutical, Managed Care, Parent, Methadone, Pregnancy, OTP, Grief, FDA, MAT, Opioid, Heroin, Senior counsel, Pharmaceutical industry

One of Pinnacle’s 8 opioid treatment programs (OTP) in the state , Winchester Treatment Services provides medication-assisted treatment (MAT), particularly methadone and suboxone, coupled with various methods of counseling and behavioral therapies at the facility.

Key Points: 
  • One of Pinnacle’s 8 opioid treatment programs (OTP) in the state , Winchester Treatment Services provides medication-assisted treatment (MAT), particularly methadone and suboxone, coupled with various methods of counseling and behavioral therapies at the facility.
  • MAT is the gold standard of care for opioid addiction.
  • The FDA-approved medicines work to curb withdrawal symptoms from heroin and pain pill addiction, prevent relapse, and help ease the physical discomfort that accompanies opioid recovery.
  • Individuals needing addiction treatment can call (859) 287-1098 for a free, confidential assessment.

Scene Health Awarded Second NIH Grant to Revolutionize Methadone Treatment, Expand Access

Retrieved on: 
Wednesday, August 9, 2023
Managed Care, Pharmaceutical, Telemedicine, Virtual Medicine, Mental Health, White House, Federal Government, Infectious Diseases, Health Technology, Health Insurance, Clinical Trials, Health, Diabetes, Public Policy, Government, Substance Abuse, Methadone, University, Taiwan Centers for Disease Control, Opioid use disorder, Substance Abuse and Mental Health Services Administration, DRS, MHealth, OUD, Research, Medicine, Person, Sale, University of Colorado, HERO, OTP, DOT, Patient, Tuberculosis, University of Washington School of Medicine, National Institute on Drug Abuse, Counselor, SAMHSA, Pharmaceutical industry, Medical device, Lancet

Scene Health (formerly emocha Mobile Health), in collaboration with the University of Washington School of Medicine, was awarded a $1.96M small business innovation research award from the National Institute on Drug Abuse.

Key Points: 
  • Scene Health (formerly emocha Mobile Health), in collaboration with the University of Washington School of Medicine, was awarded a $1.96M small business innovation research award from the National Institute on Drug Abuse.
  • The award funds phase two of a project to revolutionize methadone treatment by expanding access to remote monitoring for opioid use disorder (OUD) through Scene’s video Directly Observed Therapy (video DOT) technology.
  • During the pandemic, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed more take-home methadone doses at the provider's discretion to reduce in-person contact.
  • “Currently, SAMHSA’s regulations differentiate between a ‘supervised dose’ and a ‘take-home dose,’” said Sebastian Seiguer, CEO of Scene Health.

Pinnacle Treatment Centers Expands Services with the Opening of Front Royal, Virginia Location

Retrieved on: 
Monday, July 31, 2023
Mental Health, Hospitals, Health, Pharmaceutical, Managed Care, Methadone, PTC, Opioid use disorder, The Sundays, Employment, Residential treatment center, Environment, Patient, Family therapy, Pinnacle, Substance abuse, Nursing, Hospital

Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Front Royal, Virginia.

Key Points: 
  • Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Front Royal, Virginia.
  • With a commitment to delivering personalized and evidence-based care, Pinnacle Treatment Centers aims to make a positive impact on individuals struggling with addiction in the local community.
  • Situated in the picturesque town of Front Royal, Front Royal Treatment Center will provide a wide range of services to address the unique needs of each patient.
  • To learn more about Front Royal Treatment Center and the services provided, please visit their website .

Opioids and cocaine are a deadly combination – and 'polydrug' deaths are rising

Retrieved on: 
Monday, July 31, 2023
Blood pressure, Drug-related deaths in the United Kingdom, Dopamine, Consciousness, Drug overdose, Methamphetamine, Palpitations, Heroin, Stroke, Hyperthermia, European Monitoring Centre for Drugs and Drug Addiction, The Rev, Fentanyl, Brain, CDC, Amphetamine, Death, Man, Methylphenidate, Protein, Morphine, Cocaine, Hypoventilation, Risk, Euphoria, Korea Disease Control and Prevention Agency, Methadone, Center, Respiratory failure, Pharmaceutical industry, Drug, Cereal

Drug-related deaths associated with stimulants, such as cocaine, methamphetamine, amphetamine and methylphenidate, doubled between 2011 and 2021.

Key Points: 
  • Drug-related deaths associated with stimulants, such as cocaine, methamphetamine, amphetamine and methylphenidate, doubled between 2011 and 2021.
  • And deaths associated with using both stimulants and opioids, such as heroin, morphine, fentanyl and methadone, increased by about sevenfold over the same period.
  • Cocaine and methamphetamine are stimulant drugs, whereas opioids, such as heroin and methadone, are depressants.
  • Taken together, it can be seen that there may be a worldwide increase in polydrug-related deaths and in particular those involving both stimulants and opioids.

AliveCor and Thomas Jefferson University Hospital Partner to Evaluate KardiaMobile 6L for QT Prolongation Screening in Patients Treated for Opioid Use Disorder

Retrieved on: 
Thursday, July 20, 2023
Partnership, Senior, Opioid use disorder, ECG, NARP, Associate, QT interval, DO, MD, Patient, Guideline, Thomas Jefferson University Hospital, Methadone, Alivecor, FDA, Pharmaceutical industry, Medical device

MOUNTAIN VIEW, Calif., July 20, 2023 /PRNewswire/ -- AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced a partnership with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 20, 2023 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced a partnership with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.
  • In the six-month pilot study, healthcare professionals will use KardiaMobile 6L, the only medical-grade, six-lead personal ECG device that is FDA-cleared to measure QTc intervals, to detect QT prolongation, a potentially dangerous side effect associated with certain medications like methadone.
  • "We are excited to partner with Thomas Jefferson University Hospital on this important study that will illuminate the benefits of real-time QTc interval monitoring with KardiaMobile 6L on patients' outcomes and their treatment experience," said Patricia Baran, Senior Vice President, Enterprise North America & Biopharma Worldwide.
  • "We look forward to assessing how efficient QTc monitoring with KardiaMobile 6L increases compliance with guideline recommendations, improves the patient experience, enhances treatment, and allows for interdepartmental collaboration," said Daniel Frisch, MD, Associate Professor of Medicine Electrophysiology Section, Thomas Jefferson University Hospital.

Myths about will power and moral weakness keep people with opioid use disorder from receiving effective medications like methadone, buprenorphine and naltrexone

Retrieved on: 
Thursday, July 13, 2023
Maintenance, Methadone, Failure, Nicotine, Bureau of Medical Services (U.S. Department of State), Diabetes, Friends, Buprenorphine, Office of Inspector General, U.S. Department of Health and Human Services, Opioid use disorder, Research, Medicine, Naltrexone, Caffeine, Heroin, Death, Morphine, Risk, Euphoria, Drug, Weaning, Family, Medication, Dentistry, Birth control, Pharmaceutical industry

Methadone and buprenorphine prevent intense cravings and other symptoms of withdrawal, while naltrexone works by blocking the effects of opioids.

Key Points: 
  • Methadone and buprenorphine prevent intense cravings and other symptoms of withdrawal, while naltrexone works by blocking the effects of opioids.
  • We asked what they thought about using medication to treat opioid use disorder.
  • Across all four groups, we heard three myths about using medication for opioid use disorder.

Medication isn’t trading one drug for another

    • Many of our participants expressed the belief that using medication is the same as using opioids to get high.
    • This misperception is likely rooted in the outdated idea that recovery is defined by total abstinence from all substances, except perhaps caffeine and nicotine.

Medication is an important part of long-term recovery

    • A community member we spoke with said, “It’s a way of weaning them off everything.
    • Guidelines from the U.S. Department of Health and Human Services discourage rapid tapers and affirm that long-term use is the best way to prevent relapse, overdose and death.

Long-term treatment counts as success

    • Many of our study participants voiced the belief that long-term use of medication means the treatment did not work.
    • Just as those with high blood pressure or diabetes may need to remain on medications for the long term, so might some people with opioid use disorder.
    • Keeping people in treatment and alive through use of medications is treatment success, not failure.
    • The latest data from the U.S. Centers for Disease Control and Prevention estimates nearly 83,000 deaths in 2022 involved opioids.

Intelligent Bio Solutions Receives Guidance from U.S. FDA on a Regulatory Pathway for Expansion into the United States for its Intelligent Fingerprinting Drug Screening Cartridge

Retrieved on: 
Wednesday, June 28, 2023
Classification, Marketing, Benzodiazepine, Buprenorphine, Cocaine, Collection, Methadone, Cannabis, Substance abuse, Health, FDA, Intelligence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical device

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received guidance from the U.S. Food and Drug Administration (the “FDA”) regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge.

Key Points: 
  • NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received guidance from the U.S. Food and Drug Administration (the “FDA”) regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge.
  • The Company intends to submit a 510(k) pre-market notification for its proprietary Intelligent Fingerprinting Drug Screening Cartridge.
  • “We are pleased to receive the FDA’s preliminary assessment for our Intelligent Fingerprinting Drug Screening Cartridge, which is a key step in our expansion into the U.S. market,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
  • The system features a small, tamper-evident drug screening cartridge onto which ten fingerprint sweat samples are collected in less than a minute.

Berkshire Biomedical Announces Two Poster Presentations at the CPDD 85th Annual Scientific Meeting

Retrieved on: 
Tuesday, June 20, 2023
Communication, Travel, Opioid use disorder, Research, COPA, Berkshire, CO, AIU, Patient, Adherence (medicine), Methadone, Drug development, University of Florida College of Medicine-Jacksonville, Dentition, Safety, Pharmaceutical industry, Office supplies

DALLAS, June 20, 2023 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or the "Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, announced today that two posters on the Company's Computerized Oral Prescription Administration System (COPA) were presented yesterday at The College on Problems of Drug Development (CPDD) 85th Annual Scientific Meeting, currently being held through Wednesday, June 21, 2023 in Denver, CO. The COPA is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of controlled and non-controlled prescription medications to only an Authenticated Intended User (AIU™), upon confirmation of dual biometric identifications, (fingerprint and dentition), with the goal of enhancing patient wellness and providing remote monitoring.

Key Points: 
  • "The opportunity to present two posters at such an important scientific meeting speaks volumes about the potential technological strength and versatility of our proprietary, cloud-based, healthcare-enabled COPA device," stated John Timberlake, Chief Executive Officer of Berkshire.
  • "COPA may significantly increase the safety and effectiveness of take-home methadone medication administration for opioid use disorder, thus potentially reducing patient burden, improving clinic operational efficiencies, and enhancing patient outcomes.
  • Details of the poster presentations are below:
    Poster Author & Poster Number: John Timberlake, et al (Poster # 3007513)
    Over 500,000 people in the US receive oral liquid methadone to treat opioid use disorder, which, by law, currently is only accessible from federally certified opioid treatment programs.
  • This device may reduce barriers to treatment for methadone patients, improve clinic efficiency, and expand the flexibility of settings for methadone administration.